Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep M Llibre

Showing results (121-130 of 162) with videos related to

Pageof 17
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica|September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsJuan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Frontiers in Immunology|November 3, 2023
IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitorsHortensia Álvarez, Alicia Gutiérrez-Valencia, Ana Mariño, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2024
Major cardiovascular events after COVID-19 in people with HIVRaquel Martín-Iguacel, Sergio Moreno-Fornés, Andreu Bruguera, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
The New England Journal of Medicine|September 12, 2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infectionEsteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.
Frontiers in Medicine|July 7, 2023
Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort studyRaquel Martín-Iguacel, Mari Carmen Vazquez-Friol, Joaquin Burgos, et al.
Medicine|October 18, 2016
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort studyJosep M Llibre, Alessandro Cozzi-Lepri, Court Pedersen, et al.
Open Forum Infectious Diseases|July 18, 2025
Performance (Sensitivity and Specificity) of a New Point-of-Care Immunochromatography to Screen for Imported Chronic Schistosomiasis Among Long-Term Sub-Saharan MigrantsAlaa H A Hegazy, Olga Pérez-Quílez, Israel López-Muñoz, et al.
Pageof 17

Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
Enfermedades Infecciosas Y Microbiologia Clinica|September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsJuan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Frontiers in Immunology|November 3, 2023
IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitorsHortensia Álvarez, Alicia Gutiérrez-Valencia, Ana Mariño, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2024
Major cardiovascular events after COVID-19 in people with HIVRaquel Martín-Iguacel, Sergio Moreno-Fornés, Andreu Bruguera, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
The New England Journal of Medicine|September 12, 2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infectionEsteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.
Frontiers in Medicine|July 7, 2023
Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort studyRaquel Martín-Iguacel, Mari Carmen Vazquez-Friol, Joaquin Burgos, et al.
Medicine|October 18, 2016
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort studyJosep M Llibre, Alessandro Cozzi-Lepri, Court Pedersen, et al.
Open Forum Infectious Diseases|July 18, 2025
Performance (Sensitivity and Specificity) of a New Point-of-Care Immunochromatography to Screen for Imported Chronic Schistosomiasis Among Long-Term Sub-Saharan MigrantsAlaa H A Hegazy, Olga Pérez-Quílez, Israel López-Muñoz, et al.
Pageof 17